What is dose titration? It means starting with a low dose and changing it step by step, based on the response and side effects. The starting dose gives treatment a measured beginning. The next step depends on the medicine's plan and the prescriber's judgment.

For medicines such as tirzepatide and semaglutide, the gradual increase is meant to make digestive side effects more manageable. Reaching the highest dose isn't the definition of success.

What is dose titration on a medication label?

The official wording is usually dosage escalation, meaning an increase in the amount of medicine. Titration is broader: the dose can go up or down as the clinician weighs the result against the side effects.

The Zepbound prescribing information carries the line “Revised: 08/2026.” Section 2.1 describes a 2.5 mg weekly starting dose for four weeks. Later increases are separated by at least four weeks. It explicitly gives the reason: reducing digestive side effects.

That label distinguishes the starting dose from a maintenance dose, the amount used for ongoing treatment. It also says treatment response and tolerability, meaning how well someone handles the medicine, guide the maintenance choice.

The Wegovy prescribing information reads “Revised: 06/2026.” Section 2.2 describes four-week steps for the injection. It permits delaying escalation by four weeks when a step isn't tolerated. The tablet has a separate escalation plan.

These are facts about the named brands' labels. The full charts belong in the tirzepatide dose schedule and semaglutide dose schedule. An individual prescription comes from the prescriber.

Why GLP-1 doses start low

GLP-1 medicines act on a gut-hormone signal involved in fullness and blood sugar. Nausea, vomiting, diarrhea and constipation can accompany treatment, especially while the dose rises.

Researchers tested the pace rather than simply assuming it mattered. A 12-week tirzepatide trial enrolled 111 adults with type 2 diabetes. Its findings suggested that lower starting doses and smaller increases were associated with a more favorable side-effect pattern (Frias et al., Diabetes, Obesity and Metabolism, 2020). That small study helped inform later development; it wasn't a personal dosing guide.

A pooled analysis, which combines results from several trials, examined semaglutide in STEP 1–3. Digestive events occurred most often during or shortly after escalation. About 4 in 100 semaglutide participants, 4.3%, stopped permanently because of those events, versus 0.7% with placebo (Wharton et al., Diabetes, Obesity and Metabolism, 2022).

The same analysis found that weight loss was largely independent of digestive side effects. Feeling sick isn't a test of whether treatment is working.

Titration to effect versus fixed-schedule escalation

Titration to effect means adjusting the dose toward a measurable treatment goal, while checking side effects. Fixed-schedule escalation means the planned steps and intervals are set in advance.

A prescription can combine both. The label supplies a planned climb; response and tolerability help determine the eventual maintenance dose. A calendar alone doesn't answer whether the next increase fits.

Titration also appears outside weight management:

  • With lisinopril, a blood-pressure medicine, clinicians may start low and gradually increase the dose (MedlinePlus drug information).
  • With levothyroxine, a replacement thyroid hormone, dose adjustments commonly follow TSH, a blood marker used to assess thyroid replacement. American Thyroid Association guidance describes reassessment four to six weeks after a change (Jonklaas et al., Thyroid, 2014).

Down-titration means lowering the dose. Zepbound's label permits considering a lower maintenance dose when one isn't tolerated. Wegovy's injection label allows delaying a step and lists different maintenance choices according to the condition being treated. Those provisions are specific; they don't make every lower dose a labeled maintenance option.

How titration shows up in a prescription

A useful plan states the starting amount, the planned review point and what will determine the next step. For semaglutide or tirzepatide, the labels make both treatment response and side effects part of that decision.

That matters at follow-up. A clinician needs to know whether symptoms started after a change, whether they persisted, and how treatment is progressing. The answer may involve keeping the same dose, changing the pace or reconsidering the plan.

Tirzepatide and semaglutide prescribed through Promise are dispensed by a licensed U.S. compounding pharmacy as compounded medications, which is different from an FDA-approved product: the formulations offered here are not FDA-approved. Compounded means prepared by a pharmacy for a prescription. Brand-label evidence does not establish the safety, effectiveness or quality of a compounded preparation.

A licensed provider may still prescribe a compounded formulation; that decision is between the patient and the doctor. At Promise, a licensed provider reviews every request, and not everyone qualifies.

Mistakes people make with titration

“Skipping steps gets me there sooner.” The labels use gradual escalation to reduce digestive side effects. FDA also describes adverse-event reports involving compounded GLP-1 doses increased faster than brand-label schedules (FDA dosing concerns). Reports don't establish cause in every case. Your prescriber decides the pace.

“The starting dose must be my permanent dose.” Starting and maintenance describe different jobs. Zepbound's label calls 2.5 mg an initiation dose, rather than a maintenance option. That doesn't mean the starting amount has no biological activity.

As of October 1, 2026, the day this article was written, a study published July 28, 2026, had followed low-dose tirzepatide for six months. It analyzed 112 Japanese adults without diabetes, with doses chosen by patients and clinicians rather than randomly assigned (Amioka et al., 2026). It does not establish that two doses are equivalent or change Zepbound's labeled maintenance choices.

The separate guides to microdosing tirzepatide and microdosing semaglutide explain that different question. Your prescriber decides whether a lower-dose plan fits.

“A plateau means I need more.” A plateau, when weight stops falling, can occur during continued treatment. In STEP 5, the semaglutide group's average weight loss leveled off around week 60 and remained through week 104 (Garvey et al., Nature Medicine, 2022). A stable weight doesn't automatically call for escalation. Your prescriber decides how it fits the treatment goal.

Half-life is the time it takes the level in the blood to fall by half. The half-life glossary explains why repeated doses build up over time.

Bioavailability means how much medicine becomes available where it acts, and how quickly. The bioavailability glossary explains why the delivery route and exact preparation matter.

Milligrams measure the amount of drug. Syringe units describe volume on a particular scale; they aren't interchangeable with milligrams. The units-to-milligrams guide explains that distinction. Titration changes a prescribed drug amount, not a syringe number carried over from another prescription.

The useful question at a review is what would justify a change: the measured response, the side effects or both. That gives the next step a reason beyond the calendar.